ViiV Healthcare has announced positive results from its phase 3 program assessing the safety and efficacy of switching virologically suppressed patients from a three- or four-drug antiretroviral regimen to a two-drug regimen of dolutegravir and rilpivirine.
Immunomedics has signed a development and licensing agreement worth up to $2bn with Seattle Genetics for its experimental cancer drug.
Preliminary results from a proof-of-concept (POC) study evaluating Viking Therapeutics' VK2809 in an in vivo model of a rare orphan disorder, dubbed glycogen storage disease Ia (GSD 1a), demonstrated an encouraging effect.
GW Pharmaceuticals has unveiled positive top-line results from an exploratory Phase 2 placebo-controlled clinical study of a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in 21 patients with recurrent glioblastoma multiforme, or GBM.
Immunovaccine has announced that the UHN’s Princess Margaret Cancer Centre (PM) will carry out a Phase 2 clinical trial to assess the use of a combination of immunotherapies from Immunovaccine and Merck.
Amgen announced that the FOURIER trial assessing whether Repatha (evolocumab) reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) met its primary composite endpoint (cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or coronary revascularization) and the key secondary composite endpoint (cardiovascular death, non-fatal MI or non-fatal stroke).
Abeona Therapeutics has enrolled the first high-dose subject in the ongoing Phase 1/2 trial for ABO-102 (AAV-SGSH) in Sanfilippo Syndrome Type A.
Kainos Medicine has started phase 1 clinical trials of its Parkinson's Disease drug candidate code-named KM-819.
Worldwide Clinical Trials has been selected as Aurinia Pharmaceuticals' clinical research organization (CRO) for the AURORA phase 3 study of volcosporin to treat active lupus nephritis (LN).
Eisai has announced positive topline results from the randomized, multicenter Phase 3 trial (Study 304) evaluating the company's multiple receptor tyrosine kinase inhibitor, lenvatinib (marketed as Lenvima), for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.